UBS analyst Eliana Merle reiterated a Buy rating and $188.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).The analyst commented, "SRPT ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE